Have a personal or library account? Click to login
Squamous Cell Carcinoma Developed in Chronic Osteomyelitis Cover
Open Access
|May 2018

Abstract

Introduction. Squamous cell carcinoma is the second as frequency in malignant tumors of the skin, representing 20% of this type of cancer. Inferior lip squamous carcinoma is most frequent, of 94%, because the trauma, sunburns, smoke and radiations are more frequent. Metastasis at distance in the area with chronic osteomyelitis is a rare situation. Material and method. A 78-year-old male, treated for inferior lip carcinoma, without any oncological treatment, was admitted in our clinic for a leg tumor on the anterior part, developed over a scar after osteomyelitis treated in the adolescence. The tumor growth was quick. We decided the treatment plan from the point of view of a multidisciplinary approach, plastic surgeon-orthopedistoncologist- dermatologist. A biopsy from the extraosseous tumor was performed and after the histological confirmation, the resection of the tumor block was made. For the confirmation of the bone invasion, we had to repeat the immunohistochemistry twice because the first result was negative. Until the final decision, the patient had an external fixation on the leg. A large tissue appeared on the area of resection, the aspect being suggestive for granulation. Amputation was decided after the complementary investigations and another biopsy from the granulation tissue. Results and conclusions. Squamous cell carcinoma of the lip needs prophylactic laterocervical ganglia resection for limiting metastasis.

DOI: https://doi.org/10.2478/rojost-2018-0077 | Journal eISSN: 2544-8978 | Journal ISSN: 2601-5005
Language: English
Page range: 66 - 66
Published on: May 22, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2018 M.I. Zaharia, A.M. Oproiu, M. Costache, D. Popescu, N. Dumitrescu, A. Varga, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.